These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4038426)

  • 1. Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs.
    Rebec GV; Centore JM; White LK; Alloway KD
    Science; 1985 Jan; 227(4685):438-40. PubMed ID: 4038426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of haloperidol-induced catalepsy by ascorbic acid in rats and nonhuman primates.
    Dorris RL; Dill RE
    Pharmacol Biochem Behav; 1986 Mar; 24(3):781-3. PubMed ID: 3703914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some behavioural and EEG effects of ascorbic acid in rats.
    Wambebe C; Sokomba E
    Psychopharmacology (Berl); 1986; 89(2):167-70. PubMed ID: 3088632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascorbate antagonizes the behavioral effects of amphetamine by a central mechanism.
    White LK; Carpenter M; Block M; Basse-Tomusk A; Gardiner TW; Rebec GV
    Psychopharmacology (Berl); 1988; 94(2):284-7. PubMed ID: 2832869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy.
    Tschanz JT; Rebec GV
    Pharmacol Biochem Behav; 1988 Nov; 31(3):519-22. PubMed ID: 3251235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrastriatal infusions of ascorbate antagonize the behavioral response to amphetamine.
    White LK; Maurer M; Kraft ME; Oh C; Rebec GV
    Pharmacol Biochem Behav; 1990 Jul; 36(3):485-9. PubMed ID: 2377651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic haloperidol-amphetamine interactions and mesolimbic dopamine.
    Lynch MR; Kuhn HG; Carey RJ
    Neuropsychobiology; 1988; 19(2):97-103. PubMed ID: 3226530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine potentiates the behavioral effects of haloperidol.
    Emerich DF; Norman AB; Sanberg PR
    Psychopharmacol Bull; 1991; 27(3):385-90. PubMed ID: 1775613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437.
    Timmerman W; Tepper PG; Bohus BG; Horn AS
    Eur J Pharmacol; 1990 Jun; 181(3):253-60. PubMed ID: 1974516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blockade interacts with a neuroleptic to attenuate the conditioning of amphetamine's behavioral effects in the rat.
    DiLullo SL; Martin-Iverson MT
    Biol Psychiatry; 1992 Jun; 31(11):1143-50. PubMed ID: 1388060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation.
    Drinkenburg WH; Keith AB; Sahgal A; Andrews JS
    Behav Pharmacol; 1999 Feb; 10(1):105-11. PubMed ID: 10780307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.
    Lazzarini M; Salum C; Del Bel EA
    Psychopharmacology (Berl); 2005 Aug; 181(1):71-9. PubMed ID: 15806417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical correlates of the waltzing-shaker syndrome in the Varitint-waddler mouse.
    Cools AR
    Psychopharmacologia; 1972; 24(3):384-96. PubMed ID: 5064304
    [No Abstract]   [Full Text] [Related]  

  • 15. Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats.
    Gmiro VE; Serdyuk SE
    Bull Exp Biol Med; 2007 May; 143(5):617-9. PubMed ID: 18239784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early life stress causes refractoriness to haloperidol-induced catalepsy.
    Marrocco J; Mairesse J; Bucci D; Lionetto L; Battaglia G; Consolazione M; Ravasi L; Simmaco M; Morley-Fletcher S; Maccari S; Nicoletti F
    Mol Pharmacol; 2013 Aug; 84(2):244-51. PubMed ID: 23716620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of the behavioural effects of haloperidol and of dopamine receptor regulation by altered thyroid status.
    Crocker AD; Overstreet DH
    Psychopharmacology (Berl); 1984; 82(1-2):102-6. PubMed ID: 6420818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian changes in the destruction and effects of haloperidol in the rat.
    Campbell A; Herschel M; Sommer B; Madsen JR; Cohen BM; Baldessarini RJ
    Neuropharmacology; 1982 Jul; 21(7):663-9. PubMed ID: 6889690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.